- Home
- CCU vs GLPG Comparison
CCU vs GLPG Comparison
Compare CCU & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CCU | GLPG |
|---|---|---|
| Founded | 1850 | 1999 |
| Country | Chile | Belgium |
| Employees | N/A | 704 |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.2B |
| IPO Year | 2001 | N/A |
Fundamental Metrics
Financial Performance| Metric | CCU | GLPG |
|---|---|---|
| Price | $11.72 | $32.81 |
| Analyst Decision | Strong Sell | Buy |
| Analyst Count | 2 | 2 |
| Target Price | $12.00 | ★ $36.50 |
| AVG Volume (30 Days) | ★ 194.4K | 87.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.98% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.69 | N/A |
| Revenue Next Year | $6.15 | N/A |
| P/E Ratio | $18.35 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.35 | $22.59 |
| 52 Week High | $15.75 | $37.78 |
Technical Indicators
Market Signals| Indicator | CCU | GLPG |
|---|---|---|
| Relative Strength Index (RSI) | 25.46 | 41.98 |
| Support Level | $11.64 | $32.07 |
| Resistance Level | $12.46 | $33.56 |
| Average True Range (ATR) | 0.42 | 0.80 |
| MACD | -0.27 | -0.14 |
| Stochastic Oscillator | 3.18 | 9.50 |
Price Performance
Historical ComparisonAbout CCU Compania Cervecerias Unidas S.A.
United Breweries Co Inc is a multi-category beverage company with operations in Chile, Argentina, Bolivia, Colombia, Paraguay and Uruguay. The company is a player in each one of the beverage categories in which it participates in Chile, including beer, soft drinks, mineral and bottled water, juice, wine, cider and pisco, among others. The Company has three operating segment with respect to its revenues in the geographic areas of commercial activity: Chile; International business and Wine. It generates maximum revenue from Chile.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.